文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

混合结核分枝杆菌感染与新诊断结核病患者不良治疗结局相关,且独立于治疗前异质性耐药

Mixed Mycobacterium tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance.
PubMed 文献 · J Infect Dis · 2018-01-01

在博茨瓦纳开始一线抗结核治疗的260例新诊断结核病患者中,采用24位点MIRU-VNTR分析和靶向深度测序检测混合感染与异质性耐药,发现25例(9.6%)存在混合感染,30例(11.5%)治疗结局不良;多变量分析显示混合感染独立预测不良治疗结局,而异质性耐药感染不独立预测。

要点

  • 260例患者中混合感染25例(9.6%),不良治疗结局30例(11.5%)。
  • 异烟肼微异质性耐药11例(4.2%)、宏异质性耐药2例(0.8%)、固定耐药11例(4.2%)。
  • 利福平微异质性耐药21例(8.1%)、宏异质性耐药0例(0%)、固定耐药10例(3.8%)。

核心结论

  • 在博茨瓦纳开始一线抗结核治疗的患者中,混合感染与不良结核治疗结局相关,且独立于异质性耐药。

研究设计与样本

  • 基于博茨瓦纳开始一线抗结核治疗的新诊断结核病患者的人群样本研究。
  • 对基线原代培养分离株进行24位点分枝杆菌散在重复单位-可变数目串联重复分析检测混合感染。
  • 对基线原代培养分离株进行靶向深度测序检测异质性耐药。
  • 研究纳入260例结核病患者。

主要发现

  • 260例患者中25例(9.6%)存在混合感染,30例(11.5%)治疗结局不良。
  • 异烟肼耐药频率<0.1%的微异质性耐药11例(4.2%)、0.1%-4%的微异质性耐药2例(0.8%)、5%-94%的宏异质性耐药2例(0.8%)、≥95%的固定耐药11例(4.2%)。
  • 利福平耐药频率<0.1%的微异质性耐药21例(8.1%)、0.1%-4%的微异质性耐药0例(0%)、5%-94%的宏异质性耐药0例(0%)、≥95%的固定耐药10例(3.8%)。
  • 多变量分析中,混合感染独立预测不良治疗结局,而异质性耐药感染不独立预测不良治疗结局。

关键数值与推荐

  • 微异质性耐药定义为耐药频率<0.1%。
  • 微异质性耐药定义为耐药频率0.1%-4%。
  • 宏异质性耐药定义为耐药频率5%-94%。
  • 固定耐药定义为耐药频率≥95%。
  • 耐药频率检测靶点为inhA启动子、katG基因和rpoB基因的耐药决定域。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heteroresistant Mycobacterium tuberculosis infections (defined as concomitant infection with drug-resistant and drug-susceptible strains) may explain the higher risk of poor tuberculosis treatment outcomes observed among patients with mixed-strain M. tuberculosis infections. We investigated the clinical effect of mixed-strain infections while controlling for pretreatment heteroresistance in a population-based sample of patients with tuberculosis starting first-line tuberculosis therapy in Botswana. METHODS: We performed 24-locus mycobacterial interspersed repetitive unit-variable number tandem-repeat analysis and targeted deep sequencing on baseline primary cultured isolates to detect mixed infections and heteroresistance, respectively. Drug-sensitive, micro-heteroresistant, macro-heteroresistant, and fixed-resistant infections were defined as infections in which the frequency of resistance was <0.1%, 0.1%-4%, 5%-94%, and ≥95%, respectively, in resistance-conferring domains of the inhA promoter, the katG gene, and the rpoB gene. RESULTS: Of the 260 patients with tuberculosis included in the study, 25 (9.6%) had mixed infections and 30 (11.5%) had poor treatment outcomes. Micro-heteroresistance, macro-heteroresistance, and fixed resistance were found among 11 (4.2%), 2 (0.8%), and 11 (4.2%), respectively, for isoniazid and 21 (8.1%), 0 (0%), and 10 (3.8%), respectively, for rifampicin. In multivariable analysis, mixed infections but not heteroresistant infections independently predicted poor treatment outcomes. CONCLUSIONS: Among patients starting first-line tuberculosis therapy in Botswana, mixed infections were associated with poor tuberculosis treatment outcomes, independent of heteroresistance.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Shin SS, Modongo C, Baik Y, et al. Mixed Mycobacterium tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. J Infect Dis. 2018. PMID: 30085153. doi:10.1093/infdis/jiy480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。